Table 1 Baseline characteristics of patients with anaplastic thyroid cancer who received lenvatinib and pembrolizumab as first-line therapy
|  | Pembrolizumab + Lenvatinib (n = 5) |
|---|---|
Age, median (range), years | 65 (52–72) |
Sex, No. (%) | 5 |
    w | 2 (40) |
Year of diagnosis, median (range) | 2021 (2020–2021) |
ECOG performance status, No. (%) | Â |
    0 | 3 (60) |
    1 | 1 (20) |
    2 | 0 (0) |
    3 | 1 (20) |
UICC stage at time of diagnosis, No. (%) | 5 |
    IVA | 0 (0) |
    IVB | 1 (20), Patient 3 |
    IVC | 4 (80) |
Hypothyroidism with levothyroxine substitution, No. (%) | 3 (60) |
Locations of metastases at time of diagnosis, No. (%) | 5 |
    Lymph nodes | 4 (80) |
    Pulmonary | 4 (80) |
    Hepatic | 1 (20) |
    Bone | 3 (60) |
    Intestinal | 1 (20) |
Previous surgery (as per intention), No. (%) | 5 |
    diagnostic | 4 (80) |
    curative | 0 (0) |
    other | 1 (20), Patient 3: lobectomy + abscess drainage |
EBRT, No. (%) | 5 (100) |